EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

2‐Carboranylquinazoline: The Path to an ABCG2 Inhibitor

Philipp Stockmann iD, Lydia Kuhnert iD, Lisa Zörner, Walther Honscha iD, Evamarie Hey-Hawkins iD

ChemMedChem · 2023

DOI: 10.1002/cmdc.202300094 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2023. Verfasst von Philipp Stockmann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Inorganic Chemistry Faculty of Chemistry and Mineralogy, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany. Hauptthemen laut MEDLINE: Neoplasm Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of ATP‐binding cassette (ABC) transporter‐mediated multidrug resistance (MDR) in anti‐cancer therapy is often challenging, frequently leading to inefficiency of treatments. Cancer cells exploit efflux transporters, like the breast cancer resistance protein (BCRP, ABCG2), to secrete chemotherapeutic substances. In this study, an N ‐phenyl‐2‐carboranylquinazolin‐4‐amine ( 8 ) was designed as inorganic‐organic hybrid BCRP inhibitor. In particular, the ABCG2‐transporter inhibitor‐prominent scaffold N ‐phenylquinazolin‐4‐amine was combined with a boron−carbon cluster (carborane) moiety. Introducing a carborane at 2‐position of the quinazoline scaffold resulted in an increased inhibitory activity towards human ABCG2 (hABCG2) compared to its recently published regioisomer N ‐carboranyl‐2‐phenyl‐quinazolin‐4‐amine. The carboranylquinazoline 8 further showed the ability to reverse hABCG2‐mediated drug resistance in MDCKII‐hABCG2 cells by lowering the IC 50 value of the BCRP‐substrate mitoxantrone, similar to the standard reference and strong inhibitor Ko143, without exhibiting intrinsic toxicity in the lower micromolar ranges. These results make compound 8 a promising scaffold for the design of further BCRP inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm ProteinsAntineoplastic AgentsHumansATP Binding Cassette Transporter, Subfamily G, Member 2ATP-Binding Cassette TransportersMitoxantroneDrug Resistance, MultipleDrug Resistance, Neoplasm

Stichwörter der Autor:innen

ABCG2breast cancer resistance proteincarboranedrug resistancequinazoline

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsATP-Binding Cassette TransportersMitoxantroneAntineoplastic AgentsABCG2 protein, human

Autor:innen und Institutionen

  • Institute of Inorganic Chemistry Faculty of Chemistry and Mineralogy, Universität Leipzig, Johannisallee 29, 04103, Leipzig, Germany.
  • Institute of Pharmacology Pharmacy and Toxicology Faculty of Veterinary Medicine, Universität Leipzig, An den Tierkliniken 15, 04103, Leipzig, Germany.

ORCID-Profile: Philipp Stockmann, Lydia Kuhnert, Walther Honscha, Evamarie Hey-Hawkins

Zitieren

APA

Stockmann, P., Kuhnert, L., Zörner, L., Honscha, W., & Hey-Hawkins, E. (2023). 2‐Carboranylquinazoline: The Path to an ABCG2 Inhibitor. ChemMedChem. https://doi.org/10.1002/cmdc.202300094

Vancouver

Stockmann P, Kuhnert L, Zörner L, Honscha W, Hey-Hawkins E. 2‐Carboranylquinazoline: The Path to an ABCG2 Inhibitor. ChemMedChem. 2023. doi:10.1002/cmdc.202300094

BibTeX
@article{Stockmann2023,
  author = {Stockmann, Philipp and Kuhnert, Lydia and Zörner, Lisa and Honscha, Walther and Hey-Hawkins, Evamarie},
  title = {2‐Carboranylquinazoline: The Path to an ABCG2 Inhibitor},
  journal = {ChemMedChem},
  year = {2023},
  doi = {10.1002/cmdc.202300094}
}
Kostenlos starten →